Armata Pharmaceuticals (NYSE: ARMP) plans Phase 3 AP-SA02 trial in bacteremia

Rhea-AI Filing Summary

Armata Pharmaceuticals reported that it has received an End-of-Phase 2 written response from the U.S. Food and Drug Administration and plans to advance its intravenously administered Staphylococcus aureus bacteriophage product candidate, AP-SA02, into a Phase 3 clinical study. The planned trial will focus on patients with complicated S. aureus bacteremia, a serious bloodstream infection.

The company disclosed this update through a press release furnished as an exhibit, emphasizing that the information is being provided for informational purposes and is not deemed filed under securities laws. No financial results or transaction details are included in this report.

Insights

Biotech & Clinical Development Analyst

Armata outlines FDA Phase 2 interaction and plans a Phase 3 AP-SA02 trial.

Armata Pharmaceuticals describes the conclusion of an End-of-Phase 2 written response from the U.S. Food and Drug Administration regarding AP-SA02, its intravenously administered bacteriophage candidate targeting Staphylococcus aureus. The company plans to move AP-SA02 into a Phase 3 clinical study in complicated S. aureus bacteremia, signaling an intention to progress to late-stage testing.

An End-of-Phase 2 interaction typically helps align trial design and endpoints, but this disclosure does not detail the content of the FDA’s feedback, the Phase 3 protocol, or timing. The report is furnished under a Regulation FD-style item with no associated financing or partnership terms, so any future impact will depend on the eventual Phase 3 design, execution, and results.

The next concrete milestone highlighted here is the planned Phase 3 study in complicated S. aureus bacteremia. Further company communications or future filings would need to describe the trial start, size, endpoints, and any related funding arrangements to better understand potential implications.

false 0000921114 0000921114 2026-01-13 2026-01-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 13, 2026

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

Washington		001-37544		91-1549568
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(IRS Employer Identification No.)

	5005 McConnell Avenue Los Angeles, California		90066
	(Address of principal executive offices)		(Zip Code)

(310) 655-2928

(Registrant’s Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock		ARMP		NYSE American

Item 7.01 Regulation FD Disclosure.

On January 13, 2026, Armata Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the conclusion of an End-of-Phase 2 written response from the U.S. Food and Drug Administration and plans to advance the Company’s intravenously-administered Staphylococcus aureus (“S. aureus”) bacteriophage product candidate, AP-SA02, into a Phase 3 clinical study in complicated S. aureus bacteremia. The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated January 13, 2026.
104		Cover Page Interactive Data File (embedded within Inline XBRL document).

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 13, 2026	Armata Pharmaceuticals, Inc.
	By:	/s/ David House
	Name:	David House
	Title:	Senior Vice President, Finance and Principal Financial Officer

- 3 -

FAQ

What did Armata Pharmaceuticals (ARMP) disclose in this 8-K?

Armata Pharmaceuticals disclosed that it received an End-of-Phase 2 written response from the U.S. Food and Drug Administration and plans to advance its intravenously administered S. aureus bacteriophage product candidate, AP-SA02, into a Phase 3 clinical study in complicated S. aureus bacteremia.

Which Armata Pharmaceuticals (ARMP) drug candidate is moving toward Phase 3?

The product candidate is AP-SA02, an intravenously administered bacteriophage therapy targeting Staphylococcus aureus, which the company plans to evaluate in a Phase 3 clinical study in complicated S. aureus bacteremia.

Did Armata Pharmaceuticals report any financial results or transactions in this filing?

No. The report focuses on the clinical development update for AP-SA02 and furnishes a press release as Exhibit 99.1. It does not include financial results, financing transactions, or merger and acquisition details.

What is the regulatory status of the information Armata (ARMP) furnished?

Armata states that the information in Item 7.01 and Exhibit 99.1 is being furnished, not filed, under the Securities Exchange Act of 1934 and will not be incorporated by reference into registration statements or other documents under the Securities Act of 1933.

Which FDA stage interaction did Armata Pharmaceuticals describe for AP-SA02?

The company described the conclusion of an End-of-Phase 2 written response from the U.S. Food and Drug Administration, which precedes its plan to advance AP-SA02 into a Phase 3 clinical study.

What indication will Armata’s planned Phase 3 AP-SA02 study target?

The planned Phase 3 clinical study will target complicated Staphylococcus aureus bacteremia, a serious bloodstream infection caused by S. aureus.